Welcome to our dedicated page for Plus Therapeutics news (Ticker: PSTV), a resource for investors and traders seeking the latest updates and insights on Plus Therapeutics stock.
Plus Therapeutics, Inc. (NASDAQ: PSTV) generates a steady flow of news as a clinical-stage pharmaceutical and healthcare company focused on targeted radiotherapeutics and precision diagnostics for central nervous system (CNS) cancers. Headquartered in Houston, Texas, the company regularly reports on its clinical trial progress, regulatory interactions, capital markets activity, and expansion of its CNSide Diagnostics subsidiary.
News about Plus Therapeutics often highlights developments related to REYOBIQ™ (rhenium Re186 obisbemeda), its lead investigational radiotherapy for recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. Updates include clinical data presentations at major oncology meetings, safety and efficacy findings from the ReSPECT-GBM and ReSPECT-LM trials, and discussions with the U.S. Food and Drug Administration (FDA) on pivotal trial design and potential accelerated approval pathways.
Another key news theme is the company’s CNSide Diagnostics, LLC subsidiary and the CNSide® CSF Assay Platform. Press releases describe new state laboratory licenses, national coverage agreements with major payors, and real-world utilization metrics for the CNSide cerebrospinal fluid Tumor Cell Enumeration test used in managing leptomeningeal metastases.
Investors following PSTV can also expect announcements on financing and listing matters, such as public offerings of common stock and warrants, purchase agreements with institutional investors, and updates on Nasdaq listing compliance related to minimum bid price and equity standards. Corporate governance items, including proxy statements and stockholder meeting results, appear in both news and SEC filings.
This news page aggregates these updates so readers can track Plus Therapeutics’ clinical milestones, diagnostic platform expansion, regulatory communications, and capital markets events in one place. For those researching PSTV, it provides context on how the company is advancing its CNS cancer programs and managing its public company obligations over time.
Plus Therapeutics (Nasdaq: PSTV), a clinical-stage pharmaceutical company focused on CNS cancer treatments, has announced a major restructuring of its $15 million March 2025 equity financing. The restructuring eliminates potential dilution of up to 1.5 billion shares of common stock.
Key restructuring elements include: cancellation of warrants that could have issued 1.51 billion shares, leaving ~36 million shares issuable through amended Series B Warrants at 1:1 ratio; cancellation of ~25 million common shares or pre-funded warrants; and a provision requiring 90% of future capital raised after July 1, 2025, to repay holders at 115% of the original $0.66 per share price. The company has also filed to withdraw the related resale registration statement with the SEC.
Plus Therapeutics (PSTV) has received a delinquency notification from Nasdaq on May 21, 2025, due to delayed filing of its Q1 2025 Quarterly Report (Form 10-Q). The company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the SEC.
While this notification has no immediate impact on PSTV's Nasdaq listing, the company must submit a compliance plan by July 21, 2025. If accepted, Nasdaq may grant an extension until November 17, 2025. Plus Therapeutics states it is working to file the report promptly and expects to resume normal filing schedules for the remainder of 2025.
Plus Therapeutics (NASDAQ: PSTV) presented new data for REYOBIQ™ (rhenium Re186 obisbemeda) from its Phase 1 ReSPECT-LM trial for Leptomeningeal Metastases (LM) at the 2025 Nuclear Medicine and Neurooncology Conference. Key findings include:
The trial demonstrated significant clinical benefits with a 76% Clinical Benefit Rate (13/17 patients showing partial response or stable disease) and 87% clinical response rate based on physician evaluation. The treatment showed dose-dependent effectiveness, reaching 253Gy in Cohort 5.
Notably, 5 out of 7 patients who showed >80% reduction in LM tumor cells survived at least one year after initial treatment, with three receiving additional treatment under compassionate use. RNA sequencing revealed early tumor cell death and enhanced immune response, while maintaining a favorable safety profile with limited dose-limiting toxicities.
Plus Therapeutics (PSTV), a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system (CNS) cancers, has announced its participation in the D. Boral Capital Inaugural Global Conference. The event will take place on May 14, 2025, at The Plaza Hotel in New York City. CEO Marc H. Hedrick, M.D., will be available for one-on-one meetings from 9:00 AM to 3:00 PM ET. Interested parties can schedule meetings by contacting John Perez at jperez@dboralcapital.com.
Plus Therapeutics (PSTV) has appointed Kyle Guse, J.D., M.B.A. to its Board of Directors, where he will serve as chair of the Audit Committee and on the Compensation Committee. Guse brings 30 years of professional experience, including a decade as CFO, General Counsel and Secretary at Atossa Therapeutics, a NASDAQ-listed company focused on breast cancer treatments.
Currently serving as Chief Legal Officer at NYSE-listed DDC Enterprise , Guse's background includes roles as a partner in top international law firms and as a Certified Public Accountant with a Big 4 firm. He holds a J.D. from Santa Clara University Law School and an M.B.A. from California State University, Sacramento.
Plus Therapeutics is developing targeted radiotherapeutics for central nervous system cancers, with key products including REYOBIQ™ and CNSide.
Plus Therapeutics (PSTV) has released new data from its Phase 1 ReSPECT-LM dose escalation trial for REYOBIQ™ (rhenium Re186 obisbemeda) in treating Leptomeningeal Metastases. The data will be presented at the Nuclear Medicine and Neurooncology conference in Vienna.
Key findings include:
- Dose-dependent increase in absorbed dose to cranial and spinal subarachnoid space, reaching 253Gy in Cohort 5
- 31% of patients (5 out of 16) showed partial response in neuroimaging
- 75% Clinical Benefit Rate through day 112 based on neuroimaging
- 86% Clinical Benefit Rate based on physician evaluation
- No dose limiting toxicity in first four cohorts; grade 4 thrombocytopenia observed in Cohorts 5 and 6
RNA sequencing revealed early induction of apoptosis, followed by innate immune response and increased T cells with adaptive immune response by Day 28.
Plus Therapeutics (PSTV) has reported its Q4 and full year 2024 financial results, highlighting significant developments in its CNS cancer therapeutics programs. The company secured a $15 million private placement financing, regaining Nasdaq compliance and extending runway into 2026, along with a $2 million grant advance from CPRIT.
Key highlights include FDA brand name approval for REYOBIQ, promising Phase 1 clinical trial results showing doubled median survival rates for glioblastoma patients, and FDA Orphan Drug Designation for leptomeningeal metastases treatment. The company strengthened its management team and expanded its agreement with Telix IsoTherapeutics for Rhenium-186 supply.
Financial results show $3.6 million in cash and investments as of December 31, 2024, $5.8 million in grant revenue, and a net loss of $13.0 million ($1.95 per basic share) for 2024.
Plus Therapeutics (Nasdaq: PSTV) announces FDA's conditional acceptance of REYOBIQ™ as the proprietary name for its lead therapeutic candidate. REYOBIQ™ (rhenium Re186 obisbemeda) is currently under clinical investigation for treating Leptomeningeal Metastases (LM) and Recurrent Glioblastoma (GBM), both central nervous system (CNS) cancers.
The company must submit a request for proprietary name review when filing the marketing application (NDA). This branding initiative aims to help investigators, investors, and potential patients better connect with the rhenium-based radiotherapeutic beyond its chemical composition.
Plus Therapeutics (PSTV), a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system (CNS) cancers, has scheduled its fourth quarter and full year 2024 financial results announcement for Thursday, March 27, 2025 after market close.
The company's management team will host a conference call and webcast at 5:00 p.m. ET to discuss financial results and provide a corporate update. Participants can pre-register through a dial-in link and are advised to join 15 minutes before the start time. A replay will be available on the company's website, with the webcast remaining accessible for 90 days following the live call.
FAQ
What is the current stock price of Plus Therapeutics (PSTV)?
What is the market cap of Plus Therapeutics (PSTV)?
